Drug WatchNew Indication for Weight Loss Drug SemaglutideAschenbrenner, Diane S. MS, RN Author Information Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch: [email protected]. AJN, American Journal of Nursing 123(6):p 19, June 2023. | DOI: 10.1097/01.NAJ.0000938724.36679.23 Buy Metrics Abstract The weight loss drug semaglutide (Wegovy) is now approved for pediatric patients ages 12 and older whose body mass index categorizes them as obese. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.